TransMedics director granted 2,922 RSUs
Weill David reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Weill David reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director David Weill reported an equity compensation grant of 2,922 shares of common stock in the form of restricted stock units. Each RSU represents a contingent right to receive one share of common stock, with no cash paid per share. Following this award, Weill directly holds 15,056 shares of TransMedics common stock, reflecting a routine compensation-related increase in his ownership rather than an open-market purchase.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 2,922 | $0.00 | $0.00 |
Footnotes (1)
- F1. Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Key Figures
Key Terms
restricted stock units financial
RSUs financial
contingent right financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did TransMedics (TMDX) director David Weill report?
What does the 2,922 RSU grant mean for TransMedics (TMDX) director compensation?
What are restricted stock units (RSUs) in the TransMedics (TMDX) filing for David Weill?
AI-generated analysis. How Rhea-AI works. Not financial advice.